Trials / Unknown
UnknownNCT02586337
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 113 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Placebo | Placebo p.o. qd |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2015-10-26
- Last updated
- 2019-05-21
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02586337. Inclusion in this directory is not an endorsement.